Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain

Andrew E. Radbill, Alyssa T. Reddy, James M. Markert, J. Michael Wyss, Martin Pike, N. Shastry Akella, Niteesh Bharara, G. Yancey Gillespie

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Viral oncolytic therapy for malignant brain tumors involves local intratumoral delivery of a genetically engineered virus with tumor cell-specific lytic activity. Promising preliminary results have been achieved in preclinical models with G207, a replication-competent herpes simplex virus type 1 constructed with multiple directed mutations. Although the safety of G207 has been demonstrated in adults, application of viral oncolytic therapy to children with brain tumors has been delayed because of previous lack of data concerning the impact of a replication-competent oncolytic virus on the developing mammalian brain. In this study there was no significant difference in long-term physical development, cognitive performance, or exploratory behaviors between mice that received intracerebral inoculation of G207 or control saline at 4 days of age. However, histological examination and magnetic resonance imaging revealed frequent unilateral ventriculomegaly ipsilateral to the site of injection in only the G207 group. These results suggest that although it is unlikely that G207 will have significant adverse effects on neurodevelopmental outcomes of pediatric patients with brain tumors, an initial study of G207 in children should exclude those patients with tumors in or near the ventricular system as well as patients less than 2 years of age. Furthermore, patients in such a study will need to be closely monitored for the development of hydrocephalus.

Original languageEnglish (US)
Pages (from-to)118-129
Number of pages12
JournalJournal of NeuroVirology
Volume13
Issue number2
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Oncolytic Viruses
Simplexvirus
Brain Neoplasms
Brain
Oncogenic Viruses
Exploratory Behavior
Human Herpesvirus 1
Hydrocephalus
Magnetic Resonance Imaging
Pediatrics
Safety
Mutation
Injections
Therapeutics
Neoplasms

Keywords

  • Animal model
  • Brain tumors
  • Growth
  • Human herpesvirus 1
  • Investigational therapies
  • Learning

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology

Cite this

Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. / Radbill, Andrew E.; Reddy, Alyssa T.; Markert, James M.; Wyss, J. Michael; Pike, Martin; Akella, N. Shastry; Bharara, Niteesh; Gillespie, G. Yancey.

In: Journal of NeuroVirology, Vol. 13, No. 2, 03.2007, p. 118-129.

Research output: Contribution to journalArticle

Radbill, Andrew E. ; Reddy, Alyssa T. ; Markert, James M. ; Wyss, J. Michael ; Pike, Martin ; Akella, N. Shastry ; Bharara, Niteesh ; Gillespie, G. Yancey. / Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. In: Journal of NeuroVirology. 2007 ; Vol. 13, No. 2. pp. 118-129.
@article{a3f508c295c14fa3947ad5d368c7b546,
title = "Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain",
abstract = "Viral oncolytic therapy for malignant brain tumors involves local intratumoral delivery of a genetically engineered virus with tumor cell-specific lytic activity. Promising preliminary results have been achieved in preclinical models with G207, a replication-competent herpes simplex virus type 1 constructed with multiple directed mutations. Although the safety of G207 has been demonstrated in adults, application of viral oncolytic therapy to children with brain tumors has been delayed because of previous lack of data concerning the impact of a replication-competent oncolytic virus on the developing mammalian brain. In this study there was no significant difference in long-term physical development, cognitive performance, or exploratory behaviors between mice that received intracerebral inoculation of G207 or control saline at 4 days of age. However, histological examination and magnetic resonance imaging revealed frequent unilateral ventriculomegaly ipsilateral to the site of injection in only the G207 group. These results suggest that although it is unlikely that G207 will have significant adverse effects on neurodevelopmental outcomes of pediatric patients with brain tumors, an initial study of G207 in children should exclude those patients with tumors in or near the ventricular system as well as patients less than 2 years of age. Furthermore, patients in such a study will need to be closely monitored for the development of hydrocephalus.",
keywords = "Animal model, Brain tumors, Growth, Human herpesvirus 1, Investigational therapies, Learning",
author = "Radbill, {Andrew E.} and Reddy, {Alyssa T.} and Markert, {James M.} and Wyss, {J. Michael} and Martin Pike and Akella, {N. Shastry} and Niteesh Bharara and Gillespie, {G. Yancey}",
year = "2007",
month = "3",
doi = "10.1080/13550280601187177",
language = "English (US)",
volume = "13",
pages = "118--129",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain

AU - Radbill, Andrew E.

AU - Reddy, Alyssa T.

AU - Markert, James M.

AU - Wyss, J. Michael

AU - Pike, Martin

AU - Akella, N. Shastry

AU - Bharara, Niteesh

AU - Gillespie, G. Yancey

PY - 2007/3

Y1 - 2007/3

N2 - Viral oncolytic therapy for malignant brain tumors involves local intratumoral delivery of a genetically engineered virus with tumor cell-specific lytic activity. Promising preliminary results have been achieved in preclinical models with G207, a replication-competent herpes simplex virus type 1 constructed with multiple directed mutations. Although the safety of G207 has been demonstrated in adults, application of viral oncolytic therapy to children with brain tumors has been delayed because of previous lack of data concerning the impact of a replication-competent oncolytic virus on the developing mammalian brain. In this study there was no significant difference in long-term physical development, cognitive performance, or exploratory behaviors between mice that received intracerebral inoculation of G207 or control saline at 4 days of age. However, histological examination and magnetic resonance imaging revealed frequent unilateral ventriculomegaly ipsilateral to the site of injection in only the G207 group. These results suggest that although it is unlikely that G207 will have significant adverse effects on neurodevelopmental outcomes of pediatric patients with brain tumors, an initial study of G207 in children should exclude those patients with tumors in or near the ventricular system as well as patients less than 2 years of age. Furthermore, patients in such a study will need to be closely monitored for the development of hydrocephalus.

AB - Viral oncolytic therapy for malignant brain tumors involves local intratumoral delivery of a genetically engineered virus with tumor cell-specific lytic activity. Promising preliminary results have been achieved in preclinical models with G207, a replication-competent herpes simplex virus type 1 constructed with multiple directed mutations. Although the safety of G207 has been demonstrated in adults, application of viral oncolytic therapy to children with brain tumors has been delayed because of previous lack of data concerning the impact of a replication-competent oncolytic virus on the developing mammalian brain. In this study there was no significant difference in long-term physical development, cognitive performance, or exploratory behaviors between mice that received intracerebral inoculation of G207 or control saline at 4 days of age. However, histological examination and magnetic resonance imaging revealed frequent unilateral ventriculomegaly ipsilateral to the site of injection in only the G207 group. These results suggest that although it is unlikely that G207 will have significant adverse effects on neurodevelopmental outcomes of pediatric patients with brain tumors, an initial study of G207 in children should exclude those patients with tumors in or near the ventricular system as well as patients less than 2 years of age. Furthermore, patients in such a study will need to be closely monitored for the development of hydrocephalus.

KW - Animal model

KW - Brain tumors

KW - Growth

KW - Human herpesvirus 1

KW - Investigational therapies

KW - Learning

UR - http://www.scopus.com/inward/record.url?scp=34249091757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249091757&partnerID=8YFLogxK

U2 - 10.1080/13550280601187177

DO - 10.1080/13550280601187177

M3 - Article

C2 - 17505980

AN - SCOPUS:34249091757

VL - 13

SP - 118

EP - 129

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 2

ER -